An update on HLA alleles as pharmacogenetic markers for antiepileptic drug-induced cutaneous adverse reaction

  • Sue-Mian Then School of Pharmacy, Faculty of Science and Engineering, University of Nottingham Malaysia, Selangor, Malaysia. http://orcid.org/0000-0001-7666-934X
  • Azman Ali Raymond Neurology Department, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia.
Keywords: pharmacogenetic marker, HLA alleles, antiepileptic drugs (AEDs), cutaneous adverse drug reaction (cADR)

Abstract

Epilepsy is a common neurological disorder affecting approximately 50 million people worldwide. Antiepileptic drugs (AEDs) are commonly used to treat the disease depending, mainly on the type of seizure. However, the use of AEDs may also lead to cutaneous adverse drug reactions (cADR) such as toxic epidermal necrolysis (TEN), Stevens–Johnson syndrome (SJS), exfoliative dermatitis (ED) and drug‐induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS), which are unwanted comorbidities in epilepsy. It was first discovered that the HLA-B*15:02 allele was strongly associated with carbamazepine (CBZ)-induced SJS/TEN among Han Chinese and this led to the discovery of other HLA alleles and cytochrome P450 (CYP) genes that were significantly associated with various AED-induced cADRs across various populations.  This mini review is an update on the latest findings of the involvement of various HLA alleles and CYP alleles in cADRs caused by CBZ, phenytoin (PHT), oxcarbazepine (OXC) and lamitrogine (LTG) in different case-control studies around the world. From our review, we found that CBZ- and PHT-induced cADRs were more commonly reported than the other AEDs. Therefore, there were more robust pharmacogenetics studies related to these AEDs. OXC- and LTG-induced cADRs were less commonly reported, and so more studies are needed to validate the reported association of the newer reported HLA alleles with these AEDs. It is also important to take into account the allelic frequency within a given population before drawing conclusions about the use of these alleles as genetic markers to prevent AED-induced cADR. Overall, the current body of research point to a combination of alleles as a better pharmacogenetic marker compared to the use of a single gene as a genetic marker for AED-induced cADR.

References

Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006; 7:813-818. https://doi.org/10.2217/14622416.7.6.813

Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993; 129(1):92-96. https://doi.org/10.1001/archderm.1993.01680220104023

Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System. Epilepsia. 2018; 59(12):2318-2324. https://doi.org/10.1111/epi.14591

Buggy Y, Layton D, Fogg C, Shakir SA. Safety profile of oxcarbazepine: results from a prescription-event monitoring study. Epilepsia. 2010; 51(5):818-829. https://doi.org/10.1111/j.1528-1167.2009.02489.x

Chang CC, Ng CC, Too CL, Choon SE, Lee CK, Chung WH, et al. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. Pharmacogenomics J. 2017; 17(2):170-173. https://doi.org/10.1038/tpj.2016.10

Chang CC, Too CL, Murad S, Hussein SH. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011; 50(2):221-224. https://doi.org/10.1111/j.1365-4632.2010.04745.x

Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology. 2017; 88(1):78-86. https://doi.org/10.1212/WNL.0000000000003453

Chong KW, Chan DW, Cheung YB, Ching LK, Hie SL, Thomas T, et al. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. Arch Dis Child. 2014; 99(6):581-584. https://doi.org/10.1136/archdischild-2013-304767

Chung WH, Chang WC, Lee YS, Wu YY, Yang CH, Ho HC, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014; 312(5):525-534. https://doi.org/10.1001/jama.2014.7859

Chung WH, Hung SI, Hong HS, Shih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Steven-Johnson syndrome. Nature. 2004; 428:486. https://doi.org/10.1038/428486a

Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol. 2011; 18(9):1159-1164. https://doi.org/10.1111/j.1468-1331.2011.03361.x

Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon C-S, Dykeman J, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology. 2017; 88(3):296-303. https://doi.org/10.1212/WNL.0000000000003509

Frey N, Bodmer M, Bircher A, Rüegg S, Jick SS, Meier CR, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs. Epilepsia. 2017; 58(12):2178-2185. https://doi.org/10.1111/epi.13925

Fricke-Galindo I, Martínez-Juárez IE, Monroy-Jaramillo N, Jung-Cook H, Falfán-Valencia R, Ortega-Vázquez A, et al. HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients. Pharmacogenomics. 2014; 15(15):1881-1891. https://doi.org/10.2217/pgs.14.135

Harr T, French LE. Toxic epidermal necrolysis and Steven-Johnson syndrome. Orphanet J Rare Dis. 2010; 5:39. https://doi.org/10.1186/1750-1172-5-39

He N, Min FL, Shi YW, Guo J, Liu XR, Li BM, et al. Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles. Seizure. 2012; 21(8):614-618. https://doi.org/10.1016/j.seizure.2012.06.014

He XJ, Jian LY, He XL, Wu Y, Xu YY, Sun XJ, et al. Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China. Pharmacol Rep. 2013; 65(5):1256-1262. https://www.ncbi.nlm.nih.gov/pubmed/24399721

Hsu D, Brieva J, Silverberg N, Silverberg J. Morbidity andmortality of Stevens‐Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016; 136(7):1387-1397. https://doi.org/10.1016/j.jid.2016.03.023

Hu FY, Wu XT, An DM, Yan B, Stefan H, Zhou D. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population. Seizure. 2011; 20(2):160-162. https://doi.org/10.1016/j.seizure.2010.11.014

Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogen & Genom. 2006; 16:297-306. https://doi.org/10.1097/01.fpc.0000199500.46842.4a

Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010; 11(3):349-356. https://doi.org/10.2217/pgs.09.162

Ikeda H, Takahashi Y, Yamazaki E, Fujiwara T, Kaniwa N, Saito Y, et al. HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia. 2010; 51(2):297-300. https://doi.org/10.1111/j.1528-1167.2009.02269.x

Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008; 9(11):1617-1622. https://doi.org/10.2217/14622416.9.11.1617

Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010; 51(12):2461-2465. https://doi.org/10.1111/j.1528-1167.2010.02766.x

Kashiwagi M, Aihara M, Takahashi Y, Yamazaki E, Yamane Y, Song Y, et al. Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients. J Dermatol. 2008; 35(10):683-685. https://doi.org/10.1111/j.1346-8138.2008.00548.x

Kim SH, Lee KW, Song WJ, Jee YK, Lee SM, Kang HR, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011; 97(1-2):190-197. https://doi.org/10.1016/j.eplepsyres.2011.08.010

Kim SH, Ye YM, Palikhe NS, Kim JE, Park HS. Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2010; 10(4):280-290. https://doi.org/10.1097/ACI.0b013e32833b1eb3

Koomdee N, Pratoomwun J, Jantararoungtong T, Theeramoke V, Tassaneeyakul W, Klaewsongkram J, et al. Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population. Front Pharmacol. 2017; 8:879. https://doi.org/10.3389/fphar.2017.00879

Kulkantrakorn K, Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Prabmechai N, Vannaprasaht S, et al. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract. 2012; 12(3):202-208. https://doi.org/10.1111/j.1533-2500.2011.00479.x

Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 1984; 26(6):753-759. https://www.ncbi.nlm.nih.gov/pubmed/6489416

Lee AY, Kim MJ, Chey WY, Choi J, Kim BG. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol. 2004; 60(3):155-159. https://doi.org/10.1007/s00228-004-0753-0

Lin LC, Lai PC, Yang SF, Yang RC. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report. Kaohsiung J Med Sci. 2009; 25(2):82-86. https://doi.org/10.1016/S1607-551X(09)70045-2

Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, et al. Carbamazepine and phenytoin induced Steven-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008; 49(12):2087-2091. https://doi.org/10.1111/j.1528-1167.2008.01719.x

Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, et al. A marker for Stevens-Johnson syndrome ...: ethnicity matters. Pharmacogenomics J. 2006; 6(4):265-268. https://doi.org/10.1038/sj.tpj.6500356

Lv YD, Min FL, Liao WP, He N, Zeng T, Ma DH, et al. The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population. BMC Neurol. 2013; 13:75. https://doi.org/10.1186/1471-2377-13-75

Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimarães J. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology. 2003; 207(1):33-36. https://doi.org/10.1159/000070938

Man CBL, Kwan P, Baum L, Yu E, Lau KM, Cheng ASH, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007; 45(5):1015-1018. https://doi.org/10.1111/j.1528-1167.2007.01022.x

McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, et al. HLA-A*3101 and Carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011; 364:1134-1143. https://doi.org/10.1056/NEJMoa1013297

McCormack M, Urban TJ, Shianna KV, Walley N, Pandolfo M, Depondt C, et al. Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics. 2012; 13(4):399-405. https://doi.org/10.2217/pgs.11.165

Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009; 75(6):579-582. https://doi.org/10.4103/0378-6323.57718

Moon J, Kim TJ, Lim JA, Sunwoo JS, Byun JI, Lee ST, et al. HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption. Epilepsia. 2016; 57(11):1879-1886. https://doi.org/10.1111/epi.13566

Moon J, Park HK, Chu K, Sunwoo JS, Byun JI, Lim JA, et al. The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population. Epilepsia. 2015; 56(10):e161-167. https://doi.org/10.1111/epi.13087

Neligan A, Sander JW: The incidence and prevalence of epilepsy. In: From channels to commissioning: a practical guide to epilepsy. Edited by Rugg-Gunn FJ, Smalls JE. Lecture notes for the biannual epilepsy teaching weekend organised by the UK Chapter of International League against Epilepsy, 1987.

Nguyen DV, Chu HC, Phan MH, Craig T, Baumgart K, van Nunen S. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy. 2015; 5(2):68-77. https://doi.org/10.5415/apallergy.2015.5.2.68

Nunes VD, Sawyer L, Neilson J, Sarri G, Cross JH. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ. 2012; 344:e281. https://doi.org/10.1136/bmj.e281

Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011; 20(5):1034-1041. https://doi.org/10.1093/hmg/ddq537

Park HJ, Kim SR, Leem DW, Moon IJ, Koh BS, Park KH, et al. Clinical features of and genetic predisposition to drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients-investigating the relation between the HLA -B*4403 allele and lamotrigine. Eur J Clin Pharmacol. 2015; 71(1):35-41. https://doi.org/10.1007/s00228-014-1764-0

Park HJ, Kim YJ, Kim DH, Kim J, Park KH, Park JW, et al. HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs. Yonsei Med J. 2016; 57(1):118-126. https://doi.org/10.3349/ymj.2016.57.1.118

Pirmohamed M, Arbuckle JB, Bowman CE, Brunner M, Burns DK, Delrieu O, et al. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2007; 8(12):1661-1691. https://doi.org/10.2217/14622416.8.12.1661

Rambeck B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet. 1996; 31(4):309-324. https://doi.org/10.2165/00003088-199631040-00006

Ramírez E, Bellón T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res. 2017; 115:168-178. https://doi.org/10.1016/j.phrs.2016.11.027

Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987; 123(9):1160-1165. https://doi.org/10.1001/archderm.1987.01660330071012

Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994; 102(6):28S-30S. https://www.ncbi.nlm.nih.gov/pubmed/8006430

Rzany B, Correia O, Kelly JP, Naldi L, Auqueir A, Stern R. Risk of Steven-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. The Lancet. 1999; 353:2190-2194. https://doi.org/10.1016/S0140-6736(98)05418-X

Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry. 1996; 61(5):433-443. https://doi.org/10.1136/jnnp.61.5.433

Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol. 2003; 16(2):165-170. https://doi.org/10.1097/01.wco.0000063766.15877.8e

Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58(4):512-521. https://doi.org/10.1111/epi.13709

Shi YW, Min FL, Liu XR, Zan LX, Gao MM, Yu MJ, et al. Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. Basic Clin Pharmacol Toxicol. 2011; 109(1):42-46. https://doi.org/10.1111/j.1742-7843.2011.00681.x

Su SC, Chen CB, Chang WC, Wang CW, Fan WL, Lu LY, et al. HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians. Clin Pharmacol Ther. 2018. https://doi.org/10.1002/cpt.1190

Sukasem C, Chaichan C, Nakkrut T, Satapornpong P, Jaruthamsophon K, Jantararoungtong T, et al. Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients. J Immunol Res. 2018; 2018:2780272. https://doi.org/10.1155/2018/2780272

Sun D, Yu CH, Liu ZS, He XL, Hu JS, Wu GF, et al. Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China. J Huazhong Univ Sci Technolog Med Sci. 2014; 34(1):146-150. https://doi.org/10.1007/s11596-014-1247-7

Syu FK, Pan HY, Chuang PC, Huang YS, Cheng CY, Cheng FJ. Incidence of Stevens-Johnson syndrome following combination drug use of allopurinol, carbamazepine and phenytoin in Taiwan: A case-control study. J Dermatol. 2018; 45(9):1080-1087. https://doi.org/10.1111/1346-8138.14528

Tassaneeyakul W, Prabmeechai N, Sukasem C, Kongpan T, Konyoung P, Chumworathayi P, et al. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics. 2016; 26(5):225-234. https://doi.org/10.1097/FPC.0000000000000211

Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia. 2010; 51(5):926-930. https://doi.org/10.1111/j.1528-1167.2010.02533.x

Then SM, Rani ZZ, Raymond AA, Ratnaningrum S, Jamal R. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol. 2011; 29(3):290-293. https://www.ncbi.nlm.nih.gov/pubmed/22053601

Wal P, Wal A, Pandey U, Rai AK, Bhandari A. Genetic predisposition to oxcarbazepine induced Stevens-Johnson syndrome. Indian J Crit Care Med. 2011; 15(3):173-175. https://doi.org/10.4103/0972-5229.84904

Wang Q, Zhou JQ, Zhou LM, Chen ZY, Fang ZY, Chen SD, et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure. 2011; 20(6):446-448. https://doi.org/10.1016/j.seizure.2011.02.003

Wu XT, Hu FY, An DM, Yan B, Jiang X, Kwan P, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav. 2010; 19(3):405-408. https://doi.org/10.1016/j.yebeh.2010.08.007

Yampayon K, Sukasem C, Limwongse C, Chinvarun Y, Tempark T, Rerkpattanapipat T, et al. Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. Eur J Clin Pharmacol. 2017; 73(7):855-865. https://doi.org/10.1007/s00228-017-2250-2

Yuliwulandari R, Kristin E, Prayuni K, Sachrowardi Q, Suyatna FD, Menaldi SL, et al. Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype. Pharmacogenomics. 2017; 18(18):1643-1648. https://doi.org/10.2217/pgs-2017-0103

Zhang Y, Wang J, Zhao LM, Peng W, Shen GQ, Xue L, et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol. 2011; 67(9):885-887. https://doi.org/10.1007/s00228-011-1009-4

Published
2019-05-21
How to Cite
Then, S.-M. and Raymond, A. A. (2019) “An update on HLA alleles as pharmacogenetic markers for antiepileptic drug-induced cutaneous adverse reaction”, Neuroscience Research Notes, 2(2), pp. 1-17. doi: 10.31117/neuroscirn.v2i2.29.
Section
Mini Review